PARP (Poly ADP-ribose Polymerase) Inhibitors Market, Global Outlook and Forecast 2023-2028

Report ID: 1371508 | Published Date: Jan 2025 | No. of Page: 61 | Base Year: 2024 | Rating: 4 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Introduction to Research & Analysis Reports
    1.1 PARP (Poly ADP-ribose Polymerase) Inhibitors Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Overall Market Size
    2.1 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size: 2021 VS 2028
    2.2 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, Prospects & Forecasts: 2017-2028
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top PARP (Poly ADP-ribose Polymerase) Inhibitors Players in Global Market
    3.2 Top Global PARP (Poly ADP-ribose Polymerase) Inhibitors Companies Ranked by Revenue
    3.3 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue by Companies
    3.4 Top 3 and Top 5 PARP (Poly ADP-ribose Polymerase) Inhibitors Companies in Global Market, by Revenue in 2021
    3.5 Global Companies PARP (Poly ADP-ribose Polymerase) Inhibitors Product Type
    3.6 Tier 1, Tier 2 and Tier 3 PARP (Poly ADP-ribose Polymerase) Inhibitors Players in Global Market
        3.6.1 List of Global Tier 1 PARP (Poly ADP-ribose Polymerase) Inhibitors Companies
        3.6.2 List of Global Tier 2 and Tier 3 PARP (Poly ADP-ribose Polymerase) Inhibitors Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 by Type - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size Markets, 2021 & 2028
        4.1.2 Olaparib
        4.1.3 Talazoparib
    4.2 By Type - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue & Forecasts
        4.2.1 By Type - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, 2017-2022
        4.2.2 By Type - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, 2023-2028
        4.2.3 By Type - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Market Share, 2017-2028
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2021 & 2028
        5.1.2 Ovarian Cancer
        5.1.3 Breast Cancer
        5.1.4 Other
    5.2 By Application - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue & Forecasts
        5.2.1 By Application - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, 2017-2022
        5.2.2 By Application - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, 2023-2028
        5.2.3 By Application - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Market Share, 2017-2028
6 Sights by Region
    6.1 By Region - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2021 & 2028
    6.2 By Region - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue & Forecasts
        6.2.1 By Region - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, 2017-2022
        6.2.2 By Region - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, 2023-2028
        6.2.3 By Region - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Market Share, 2017-2028
    6.3 North America
        6.3.1 By Country - North America PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, 2017-2028
        6.3.2 US PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
        6.3.3 Canada PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
        6.3.4 Mexico PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
    6.4 Europe
        6.4.1 By Country - Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, 2017-2028
        6.4.2 Germany PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
        6.4.3 France PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
        6.4.4 U.K. PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
        6.4.5 Italy PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
        6.4.6 Russia PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
        6.4.7 Nordic Countries PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
        6.4.8 Benelux PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
    6.5 Asia
        6.5.1 By Region - Asia PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, 2017-2028
        6.5.2 China PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
        6.5.3 Japan PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
        6.5.4 South Korea PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
        6.5.5 Southeast Asia PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
        6.5.6 India PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
    6.6 South America
        6.6.1 By Country - South America PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, 2017-2028
        6.6.2 Brazil PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
        6.6.3 Argentina PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, 2017-2028
        6.7.2 Turkey PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
        6.7.3 Israel PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
        6.7.4 Saudi Arabia PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
        6.7.5 UAE PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, 2017-2028
7 Players Profiles
    7.1 AbbVie
        7.1.1 AbbVie Corporate Summary
        7.1.2 AbbVie Business Overview
        7.1.3 AbbVie PARP (Poly ADP-ribose Polymerase) Inhibitors Major Product Offerings
        7.1.4 AbbVie PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue in Global Market (2017-2022)
        7.1.5 AbbVie Key News
    7.2 Pfizer
        7.2.1 Pfizer Corporate Summary
        7.2.2 Pfizer Business Overview
        7.2.3 Pfizer PARP (Poly ADP-ribose Polymerase) Inhibitors Major Product Offerings
        7.2.4 Pfizer PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue in Global Market (2017-2022)
        7.2.5 Pfizer Key News
    7.3 AstraZeneca
        7.3.1 AstraZeneca Corporate Summary
        7.3.2 AstraZeneca Business Overview
        7.3.3 AstraZeneca PARP (Poly ADP-ribose Polymerase) Inhibitors Major Product Offerings
        7.3.4 AstraZeneca PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue in Global Market (2017-2022)
        7.3.5 AstraZeneca Key News
    7.4 GlaxoSmithKline
        7.4.1 GlaxoSmithKline Corporate Summary
        7.4.2 GlaxoSmithKline Business Overview
        7.4.3 GlaxoSmithKline PARP (Poly ADP-ribose Polymerase) Inhibitors Major Product Offerings
        7.4.4 GlaxoSmithKline PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue in Global Market (2017-2022)
        7.4.5 GlaxoSmithKline Key News
    7.5 Clovis Oncology
        7.5.1 Clovis Oncology Corporate Summary
        7.5.2 Clovis Oncology Business Overview
        7.5.3 Clovis Oncology PARP (Poly ADP-ribose Polymerase) Inhibitors Major Product Offerings
        7.5.4 Clovis Oncology PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue in Global Market (2017-2022)
        7.5.5 Clovis Oncology Key News
    7.6 Everest Pharmaceuticals
        7.6.1 Everest Pharmaceuticals Corporate Summary
        7.6.2 Everest Pharmaceuticals Business Overview
        7.6.3 Everest Pharmaceuticals PARP (Poly ADP-ribose Polymerase) Inhibitors Major Product Offerings
        7.6.4 Everest Pharmaceuticals PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue in Global Market (2017-2022)
        7.6.5 Everest Pharmaceuticals Key News
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer

List of Tables
    Table 1. PARP (Poly ADP-ribose Polymerase) Inhibitors Market Opportunities & Trends in Global Market
    Table 2. PARP (Poly ADP-ribose Polymerase) Inhibitors Market Drivers in Global Market
    Table 3. PARP (Poly ADP-ribose Polymerase) Inhibitors Market Restraints in Global Market
    Table 4. Key Players of PARP (Poly ADP-ribose Polymerase) Inhibitors in Global Market
    Table 5. Top PARP (Poly ADP-ribose Polymerase) Inhibitors Players in Global Market, Ranking by Revenue (2021)
    Table 6. Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue by Companies, (US$, Mn), 2017-2022
    Table 7. Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Share by Companies, 2017-2022
    Table 8. Global Companies PARP (Poly ADP-ribose Polymerase) Inhibitors Product Type
    Table 9. List of Global Tier 1 PARP (Poly ADP-ribose Polymerase) Inhibitors Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 10. List of Global Tier 2 and Tier 3 PARP (Poly ADP-ribose Polymerase) Inhibitors Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 11. By Type – Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2021 & 2028
    Table 12. By Type - PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue in Global (US$, Mn), 2017-2022
    Table 13. By Type - PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue in Global (US$, Mn), 2023-2028
    Table 14. By Application – Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2021 & 2028
    Table 15. By Application - PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue in Global (US$, Mn), 2017-2022
    Table 16. By Application - PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue in Global (US$, Mn), 2023-2028
    Table 17. By Region – Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2021 & 2028
    Table 18. By Region - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (US$, Mn), 2017-2022
    Table 19. By Region - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (US$, Mn), 2023-2028
    Table 20. By Country - North America PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2022
    Table 21. By Country - North America PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2023-2028
    Table 22. By Country - Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2022
    Table 23. By Country - Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2023-2028
    Table 24. By Region - Asia PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2022
    Table 25. By Region - Asia PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2023-2028
    Table 26. By Country - South America PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2022
    Table 27. By Country - South America PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2023-2028
    Table 28. By Country - Middle East & Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2022
    Table 29. By Country - Middle East & Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2023-2028
    Table 30. AbbVie Corporate Summary
    Table 31. AbbVie PARP (Poly ADP-ribose Polymerase) Inhibitors Product Offerings
    Table 32. AbbVie PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (US$, Mn), (2017-2022)
    Table 33. Pfizer Corporate Summary
    Table 34. Pfizer PARP (Poly ADP-ribose Polymerase) Inhibitors Product Offerings
    Table 35. Pfizer PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (US$, Mn), (2017-2022)
    Table 36. AstraZeneca Corporate Summary
    Table 37. AstraZeneca PARP (Poly ADP-ribose Polymerase) Inhibitors Product Offerings
    Table 38. AstraZeneca PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (US$, Mn), (2017-2022)
    Table 39. GlaxoSmithKline Corporate Summary
    Table 40. GlaxoSmithKline PARP (Poly ADP-ribose Polymerase) Inhibitors Product Offerings
    Table 41. GlaxoSmithKline PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (US$, Mn), (2017-2022)
    Table 42. Clovis Oncology Corporate Summary
    Table 43. Clovis Oncology PARP (Poly ADP-ribose Polymerase) Inhibitors Product Offerings
    Table 44. Clovis Oncology PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (US$, Mn), (2017-2022)
    Table 45. Everest Pharmaceuticals Corporate Summary
    Table 46. Everest Pharmaceuticals PARP (Poly ADP-ribose Polymerase) Inhibitors Product Offerings
    Table 47. Everest Pharmaceuticals PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue (US$, Mn), (2017-2022)
List of Figures
    Figure 1. PARP (Poly ADP-ribose Polymerase) Inhibitors Segment by Type in 2021
    Figure 2. PARP (Poly ADP-ribose Polymerase) Inhibitors Segment by Application in 2021
    Figure 3. Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Overview: 2021
    Figure 4. Key Caveats
    Figure 5. Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size: 2021 VS 2028 (US$, Mn)
    Figure 6. Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, 2017-2028 (US$, Mn)
    Figure 7. The Top 3 and 5 Players Market Share by PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue in 2021
    Figure 8. By Type - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Market Share, 2017-2028
    Figure 9. By Application - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Market Share, 2017-2028
    Figure 10. By Region - Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Market Share, 2017-2028
    Figure 11. By Country - North America PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Market Share, 2017-2028
    Figure 12. US PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
    Figure 13. Canada PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
    Figure 14. Mexico PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
    Figure 15. By Country - Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Market Share, 2017-2028
    Figure 16. Germany PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
    Figure 17. France PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
    Figure 18. U.K. PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
    Figure 19. Italy PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
    Figure 20. Russia PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
    Figure 21. Nordic Countries PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
    Figure 22. Benelux PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
    Figure 23. By Region - Asia PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Market Share, 2017-2028
    Figure 24. China PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
    Figure 25. Japan PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
    Figure 26. South Korea PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
    Figure 27. Southeast Asia PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
    Figure 28. India PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
    Figure 29. By Country - South America PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Market Share, 2017-2028
    Figure 30. Brazil PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
    Figure 31. Argentina PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
    Figure 32. By Country - Middle East & Africa PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Market Share, 2017-2028
    Figure 33. Turkey PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
    Figure 34. Israel PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
    Figure 35. Saudi Arabia PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
    Figure 36. UAE PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue, (US$, Mn), 2017-2028
    Figure 37. AbbVie PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 38. Pfizer PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 39. AstraZeneca PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 40. GlaxoSmithKline PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 41. Clovis Oncology PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 42. Everest Pharmaceuticals PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
61
Frequently Asked Questions
PARP Inhibitors Market report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
PARP Inhibitors Market report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
PARP Inhibitors Market report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports